Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.

Xiaotong LiLiyuan ZhouMartina GagglAlan C KinlawZhuoyue GouYang XuJingkai WeiTiansheng Wang

Published in: International journal of clinical pharmacy (2023)

In COVID-19 patients, we observed diminishing signals of remdesivir-associated AKI over time and no significant signal in the most recent quarter, suggesting remdesivir might not be nephrotoxic.

Keyphrases

acute kidney injury
drug administration
sars cov
cardiac surgery
coronavirus disease
adverse drug
electronic health record
emergency department
big data
human health
risk assessment
machine learning
climate change